Lamotrigine High‐Dose Tolerability and Safety in Patients with Epilepsy: A Double‐Blind, Placebo‐Controlled, Eleven‐Week Study
1996; Wiley; Volume: 37; Issue: 9 Linguagem: Inglês
10.1111/j.1528-1157.1996.tb00038.x
ISSN1528-1167
AutoresFumisuke Matsuo, Patricia E. Gay, Jack A. Madsen, Keith G. Tolman, Douglas E. Rollins, Marcus E. Risner, Allen A. Lai,
Tópico(s)Drug Transport and Resistance Mechanisms
ResumoSummary: Purpose: This study was undertaken to evaluate the dose tolerability and safety of a chronic ascending twice‐daily (b.i.d.) dosage regimen of 700 mg/day larnotrigine (LTG) and to include determination of the LTG pharmacokinetic profile at doses 500 mg/day in patients receiving concomitant enzyme‐inducing antiepileptic drugs (AEDs). Methods: Twelve adult male epileptic patients treated with enzyme‐inducing AEDs received 700 mg/day (b.i.d.) oral LTG (n = 8) or placebo (controls, n = 4). For 3 weeks, as outpatients they had their LTG dosage increased from 100 to 400 mg/day. Then, in a clinical research study unit, patients received regimens of 500, 600, and 700 mg/day for 1 week each. Controls received matching placebo in the same sequence. At study end, dosages were tapered in 2 weeks. Follow‐up evaluations were made 7 days later. Results: Five LTG patients tolerated 700 mg/day for 1 week. LTG was reduced to 600 mg/day in a patient with mild diplopia and to 500 mg/day in a patient with mild oscillopsia and diplopia. One patient discontinued 300‐mg/day therapy with a moderately intense diffuse papular skin rash, attributed to LTG. Headache, drowsiness, faintness, and diplopia, the common adverse events (AEs), were mild to moderate in intensity and occurred in 50–75% of patients in both groups (except for diplopia, occurring only with LTG). Concomitant AED plasma concentrations were not markedly changed by LTG. LTG pharmacokinetics were linear over the range of 500–700 mg/day. Conclusions: LTG doses 700 mg/day can be tolerated in patients receiving concomitant enzyme‐inducing AEDs.
Referência(s)